A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether
 GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared
 to vehicle of 2.8% saline alone.
Inclusion Criteria:

 -  Body mass index (BMI) from ≥ 19 to ≤ 30 kg/m2

 -  Normal ECG, with no history or evidence of myocardial infarction, QT prolongation, or
 ventricular arrhythmias

 -  Normal (or abnormal but not clinically significant) blood pressure (BP) and heart
 rate(HR)

 -  History of lifetime smoking < 5 pack-years (ie, 1 pack per day x 1 year = 1
 pack-year)and non-smokers of at least 60 days duration prior to Screening

 -  Negative screening tests for drugs of abuse (including alcohol)

 -  Hepatitis B (HBV) surface antigen negative

 -  Hepatitis C (HCV) antibody negative

 -  HIV-1, 2 antibody negative

 -  Male subjects who are sexually active must be willing to use highly effective
 contraception from the Baseline Visit through completion of the study and continuing
 for at least 90 days from the date of the last dose of study drug

 -  Male subjects must refrain from sperm donation from the Baseline Visit through
 completion of the study and continuing for at least 90 days from the date of the last
 dose of study drug

 -  Females of childbearing potential must have a negative serum pregnancy test

 -  Females of childbearing potential must agree to utilize protocol recommended highly
 effective contraception methods from Screening throughout the duration of study
 treatment and for 30 days following the last dose of study drug

 Exclusion Criteria:

 -  Female subjects who are pregnant or lactating

 -  History of anaphylactic reaction to any drug

 -  Have previously participated in an investigational trial involving administration of
 any investigational compound within 30 days prior to the study drug dosing

 -  Presence or history of extrinsic allergy requiring treatment; hay fever is allowed
 unless it is active or has required treatment within the previous 2 months

 -  Have donated blood within 56 days of study dosing

 -  Presence or history of any pulmonary diseases (ie, asthma, emphysema, chronic
 bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF),
 bronchiectasis, interstitial lung disease)

 -  Major surgery within 6 months of Screening

 -  Experienced symptoms of recent acute upper or lower respiratory tract infection
 requiring treatment within the 2 weeks prior to Screening

 -  Have had any radiation in the past year that would cause the subject exceed
 recommended limits by participating in this study protocol